
#189: New imaging in MS: understanding progression and finding better treatments | ECTRIMS 2026
How could new imaging in MS help us understand progression and develop better treatments?
In this episode, I explore key insights from Daniel Reich's MSToronto2026 lecture and related research. Learn what paramagnetic rim lesions can reveal about chronic inflammation, why MRI findings and biological treatment effects may tell different stories, and how imaging could help identify who benefits from emerging therapies.
I also discuss tolebrutinib, the HERCULES trial, and the disappointment surrounding the US regulatory setback, alongside its EU authorisation and important safety considerations.
Topics include:
- Chronic inflammation and progression without relapses
- Paramagnetic rim lesions and the exploratory BRaKe-MS study
- Imaging biomarkers for better clinical trials
- Tolebrutinib: evidence, limitations, and treatment access
This episode is my interpretation of the lecture and research, rather than an interview with Daniel Reich.
Research and resources
- Corresponding blog article von MS-Perspektive: https://ms-perspektive.de/en/189-daniel-reich-ectrims-2026/
- HERCULES trial: tolebrutinib in non-relapsing secondary progressive MS
- Chronic active MS: research connecting imaging with tissue biology
- A mechanism-driven framework for MS progression
- European Medicines Agency: Cenrifki / tolebrutinib
- Sanofi's December 2025 announcement on the FDA decision
---
See you soon and try to make the best out of your life,
Nele
For more information and positive thoughts, subscribe to my newsletter for free.
Click here for an overview of all podcast episodes published so far.
Altri episodi di "MS-Perspektive - The Multiple Sclerosis Podcast"



Non perdere nemmeno un episodio di “MS-Perspektive - The Multiple Sclerosis Podcast”. Iscriviti all'app gratuita GetPodcast.








